Depends how you look at it

[Autumnlicious]

Drug policymakers had hoped Marinol would be "a godsend," according to Mark Kleiman, director of the Drug Policy Analysis Program at UCLA's School of Public Affairs. "[Marinol] wasn't any fun and made the user feel bad," Kleiman says, "so it could be approved without any fear that it would penetrate the recreational market, and then used as a club with which to beat back the advocates of whole cannabis as a medicine." Kleiman thinks that Sativex might succeed where Marinol failed, not only because evidence from GW's clinical trials might convince regulators that it works, but also because GW is poised to "persuade the drug warriors that getting Sativex approved fast is the best way to block the medical marijuana movement."

REF: http://motherjones.com/print/16303

Of course, we all know the UCLA School of Public Affairs is a totally biased source.